This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Buccal prochlorperazine maleate
Description: Emezine is a formulation of prochlorperazine maleate that is placed between the upper lip and gum for transbuccal absorption, which is absorption into the bloodstream through the cheek.
The active ingredient of Emezine, Prochlorperazine, is a highly potent neuroleptic that has been approved in the United States since 1956. Prochlorperazine, a piperazine phenothiazine related to high-potency neuroleptics such as perphenazine, is used as an antiemetic and antipsychotic agent in the management of nausea and vomiting. It shares many of the actions and adverse effects of the antipsychotics. The antiemetic effects of prochlorperazine can be attributed to dopamine receptor blockade. Prochlorperazine also blocks anticholinergic and alpha-adrenergic receptors, the blockade of alpha(1)-adrenergic receptors resulting in sedation, muscle relaxation, and hypotension.
In July 2014, Reckitt Benckiser announced that it is pursuing a demerger of the RB Pharmaceuticals business with a separate UK listing. In December 2014, Reckitt Benckiser completed the demerger of the Reckitt Benckiser Pharmaceuticals business with a separate UK listing under the name of Indivior PLC.
Accentia and Arius (BDSI)
In March 2004, Accentia obtained exclusive U.S. distribution rights to Emezine, a product for control of nausea and vomiting from Arius, a wholly-owned subsidiary of BioDelivery Sciences International (BDSI).
Arius holds an exclusive license to the Emezine product for the U.S. from Reckitt Benckiser. Under Accentia's distribution agreement with Arius, the company has the exclusive right to market, promote, and distribute Emezine in the U.S. for the duration of the distribution agreement, which expires upon termination of Arius' license agreement with Reckitt Benckiser. The agreement provides that Arius will sell the product to...See full deal structure in Biomedtracker
Pink Sheet BDSI BEMA fentanyl NDA in Q2’07
Additional information available to subscribers only: